	US 12,221,477 B2
	TGF-β3 specific antibodies and methods and uses thereof
Jacques Van Snick, Brussels (BE); and Catherine Uyttenhove, Brussels (BE)
Assigned to Ludwig Institute for Cancer Research, Ltd., New York, NY (US)
Filed by LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD., New York, NY (US)
Filed on Sep. 23, 2022, as Appl. No. 17/951,440.
Application 17/951,440 is a division of application No. 16/913,067, filed on Jun. 26, 2020, granted, now 11,485,780.
Application 16/913,067 is a division of application No. 15/580,746, granted, now 10,723,793, issued on Jul. 28, 2020, previously published as PCT/US2016/036965, filed on Jun. 10, 2016.
Claims priority of provisional application 62/174,896, filed on Jun. 12, 2015.
Prior Publication US 2023/0287094 A1, Sep. 14, 2023
Int. Cl. C07K 16/22 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6845 (2017.08); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/30 (2013.01); G01N 33/57488 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 45/06 (2013.01); C07K 2317/33 (2013.01); C07K 2317/54 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); G01N 2333/495 (2013.01)]

36 Claims

1. A method for treatment of cancer or reducing recurrence or metastasis of cancer in a mammal wherein transforming growth factor beta 3 (TGF-β3) is expressed in a tumor or the cancer which comprises administering to said mammal an effective amount of an antibody or antigen binding fragment thereof which recognizes human and mouse TGF-β3 and which neutralizes activity of TGF-β3, which is an antibody or fragment comprising:

(a) a light chain variable region comprising a CDR1 sequence KASQSVINDVA (SEQ ID NO:1) or KASQSVINAVA (SEQ ID NO:7), a CDR2 sequence YASNRYT (SEQ ID NO:2), and a CDR3 sequence QQDYSSPYT (SEQ ID NO:3), and a heavy chain variable region sequence comprising a CDR1 sequence SSWMH (SEQ ID NO:4) or SSWIH (SEQ ID NO:8), a CDR2 sequence RIFPGDGDTIYNGNFKG (SEQ ID NO:5) or RIYPGDGDTNYTGKFKG (SEQ ID NO:9), and a CDR3 sequence RMITTQAAMDY (SEQ ID NO:6);

(b) a light chain variable region comprising a CDR1 sequence KSSQSLLNSGNQKNYLA (SEQ ID NO: 10), a CDR2 sequence GASTRES (SEQ ID NO:11), and a CDR3 sequence QNDHGFPLT (SEQ ID NO:12), and a heavy chain variable region sequence comprising a CDR1 sequence DYYIN (SEQ ID NO:13), a CDR2 sequence KIGPGTGRTYYNEKFKG (SEQ ID NO:14), and a CDR3 sequence YYGWGYAMDY (SEQ ID NO:15); or

(c) a light chain variable region comprising a CDR1 sequence RSSQSLIHSHGNTYLH (SEQ ID NO: 16), a CDR2 sequence KLSNRFS (SEQ ID NO:17), and a CDR3 sequence SQSTHVPFT (SEQ ID NO:18), and a heavy chain variable region sequence comprising a CDR1 sequence SYWIT (SEQ ID NO:19), a CDR2 sequence DIFPGTGSTNYNEKFKT (SEQ ID NO:20), and a CDR3 sequence KLGPNYAVDY (SEQ ID NO:21).